Clinical trial · Observational
Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC
Multicenter Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in the Treatment of Patients With Metastatic Colorectal Cancer
NCT07494578CI-TRIAL-00106638FLOWERactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will enroll patients with metastatic colorectal cancer treated with the combination of Trifluridine/Tipiracile and Bevacizumab across 15 italian centers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer Metastatic | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fluoropyrimidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall Survival
- timeFrame
- up to 30 months from the date of treatments' start
- description
- Time from start of the treatment to death from any cause up to 30 months from the date of treatments' start.
- measure
- Progression-free survival
- timeFrame
- up to 30 months from the date of treatments' start
- description
- time from the start of the treatment to disease progression or death from any cause, whichever occurred first, up to 30 months from the date of treatments' start.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years; * ECOG PS 0-2; * Histologic diagnosis of colorectal cancer; * Treatment with fluoropyrimidine plus bevacizumab. Exclusion Criteria: * ECOG PS ≥3; * Absence of histologic diagnosis.
References
Publications (0)
Data not yet available
No reference posted for this study.